TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34914258
Drug: Compound Chamomile
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Chamomile and Lidocaine Hydrochloride Gel
Study: 33714700
Drug: Z‐track injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z‐track injection method
Study: 33831770
Drug: Add-on yoga
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on yoga treatment
Study: 33831770
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU - wait-list control)
Study: 36107614
Drug: Esmolol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1.0 mg/kg bolus before intubation, continuous infusion during surgery, and 1.0 mg/kg bolus after surgery)
Study: 36107614
Drug: Esmolol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1.0 mg/kg bolus before intubation, continuous infusion during surgery, and 1.0 mg/kg bolus after surgery) + Ramosetron (0.3 mg after surgery)
Study: 36107614
Drug: Ramosetron (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3 mg after surgery)
Study: 36267757
Drug: Individualized pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Individualized pharmaceutical care
Study: 32556539
Drug: Imeglimin 2250
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 2250 mg
Study: 32556539
Drug: Imeglimin 6000
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 6000 mg
Study: 34240819
Drug: Low-dose aerobic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aerobic exercise (150 min/week)
Study: 34240819
Drug: High-dose aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerobic exercise (300 min/week)
Study: 33573133
Drug: H2‐rich calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2‐rich calcium powder (HCP) (1500 mg/day, containing 2.544 µg/day of H2)
Study: 33573133
Drug: H2‐depleted placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2‐depleted placebo (1500 mg/day)
Study: 34758017
Drug: 2-dose ivermectin-based
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-dose ivermectin-based MDA (IVM-2)
Study: 34758017
Drug: 1-dose ivermectin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose ivermectin-based MDA (IVM-1)
Study: 34758017
Drug: Screen and
Normalized name: SPF30 Sunscreen and SPF15 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screen and treat with topical permethrin 5% (SAT)
Study: 33574421
Drug: Investigational infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational infant formulas with 0.8 g/100 ml scGOS/lcFOS and Bifidobacterium breve M‐16V at either 1 × 104 cfu/ml or 1 × 106 cfu/ml
Study: 32232776
Drug: JuniorLEAP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: JuniorLEAP group therapy programme
Study: 35862897
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation (all treatment arms)
Study: 32692124
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation (CR) intervention involving weekly individual sessions with a therapist and practice of computerized CR exercises between sessions.
Study: 33742060
Drug: Molecular hydrogen
Normalized name: Molecular hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molecular hydrogen (H2) supplement
Study: 36316077
Drug: Online individualised
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online individualised therapy group (ITG) receiving professional advice on LBP and musculoskeletal problems via online interview and email for 6 months.
Study: 34225091
Drug: 12-month exercise
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month exercise trial after adjuvant treatment
Study: 32271073
Drug: Metacognitive Reflection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Reflection and Insight Therapy (MERIT)
Study: 34125440
Drug: Delayed endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed endoscopic dacryocystorhinostomy (En-DCR) after 2 to 5 days of antibiotic treatment
Study: 32009442
Drug: Individual computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual computer magnanimous therapy
Study: 32009442
Drug: Group computer
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group computer magnanimous therapy
Study: 34902530
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus Bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks)
Study: 34845428
Drug: ABMDC (Autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABMDC (Autologous Bone Marrow-Derived Chondrocytes), single injection of 5 million
Study: 34845428
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment they were taking)
Study: 32308128
Drug: Heparin‐coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐coated circuit (control group)
Study: 36253971
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 40 mL of 0.375% ropivacaine
Study: 36253971
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 40 mL of normal saline
Study: 32905675
Drug: Eflornithine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine plus Sulindac (750 mg eflornithine, 150 mg sulindac, both once daily for up to 48 months)
Study: 32905675
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg once daily for up to 48 months)
Study: 32905675
Drug: Eflornithine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine (750 mg once daily for up to 48 months)
Study: 32905675
Drug: Eflornithine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine plus Sulindac in rectal or ileal pouch polyposis patients
Study: 32905675
Drug: Sulindac in
Normalized name: Product containing sulindac in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac in rectal or ileal pouch polyposis patients
Study: 32905675
Drug: Eflornithine in
Normalized name: eflornithine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine in rectal or ileal pouch polyposis patients
Study: 35980649
Drug: Etoposide plus
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide plus cisplatin (EP) - etoposide (100 mg/m2/d on days 1, 2, and 3) and cisplatin (80 mg/m2/d on day 1) every 3 weeks
Study: 35980649
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus cisplatin (IP) - irinotecan (60 mg/m2/d on days 1, 8, and 15) and cisplatin (60 mg/m2/d on day 1) every 4 weeks
Study: 33051814
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration anesthesia (1.5 ml of 2% lidocaine with 1:80,000 epinephrine)
Study: 33051814
Drug: Buccal and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal and lingual infiltration anesthesia (1.5 ml of 2% lidocaine with 1:80,000 epinephrine by buccal injection and 0.3 ml of the same solution injected into the lingual side)
Study: 36346210
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose isotretinoin (0.6 mg/kg/day)
Study: 36346210
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose isotretinoin (0.3 mg/kg/day)
Study: 33413515
Drug: Gelatin sponge
Normalized name: ABSORBABLE GELATIN SPONGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin sponge impregnated with mixed anti-inflammatory drugs
Study: 38184642
Drug: In-person cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person cognitive behavioral therapy (CBT)
Study: 35953474
Drug: Iclepertin (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclepertin (2, 5, 10, or 25 mg)
Study: 33034639
Drug: Simple daily
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple daily sweepstakes group
Study: 35228163
Drug: CBT weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT weekly
Study: 35228163
Drug: CBT twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT twice weekly
Study: 35228163
Drug: IPT weekly
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPT weekly
Study: 35228163
Drug: IPT twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPT twice weekly
Study: 32996689
Drug: Active dichoptic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active dichoptic video game treatment (n = 12)
Study: 36178734
Drug: Pomalidomide (POM)
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide (POM) capsules, 4 mg
Study: 36178734
Drug: Pomalidomide (POM)
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide (POM) capsules with high-fat meals
Study: 36178734
Drug: Pomalidomide (POM)
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide (POM) capsules
Study: 36235628
Drug: H2-rich calcium
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-rich calcium powder (HCP) (1500 mg, containing 2.544 μg of H2)
Study: 36235628
Drug: H2-depleted placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-depleted placebo (1500 mg)
Study: 36375185
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.5 mg (Group M)
Study: 36375185
Drug: Intrathecal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dexmedetomidine 0.5 µg/kg (Group D)
Study: 36375185
Drug: Morphine 0.5
Normalized name: morphine 0.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.5 mg with dexmedetomidine 0.5 µg/kg (Group MD)
Study: 36397441
Drug: Phototherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phototherapy + Bifidobacterium animalis subsp. lactis CP-9 (n=43; 5×10^9 CFU/capsule)
Study: 35012478
Drug: Continuous (weekly)
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous (weekly) use of a clinical decision support system (CDSS) for medication optimization.
Study: 32574011
Drug: Tazarotene 0.045%
Normalized name: TAZAROTENE 0.045% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.045% lotion and Vehicle
Study: 32809003
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1500 mg), hydrocortisone (50 mg), thiamine (100 mg) every 6 hours for 4 days (n=103)
Study: 38320162
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0 to 3.0)
Study: 34382875
Drug: Ocrelizumab (OCR)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab (OCR) 600 mg intravenously every 24 weeks
Study: 33587505
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg VRC01
Study: 33587505
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg VRC01
Study: 32142491
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) with 10 mL of ropivacaine 0.08% and sufentanyl 0.3 μg/mL at intervals of 30 min
Study: 32142491
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) with 10 mL of ropivacaine 0.08% and sufentanyl 0.3 μg/mL at intervals of 40 min
Study: 32142491
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) with 10 mL of ropivacaine 0.08% and sufentanyl 0.3 μg/mL at intervals of 50 min
Study: 32142491
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) with 10 mL of ropivacaine 0.08% and sufentanyl 0.3 μg/mL at intervals of 60 min
Study: 32080941
Drug: Functional enrichment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional enrichment of current forest patches
Study: 32080941
Drug: Multi-species plantations
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-species plantations in previously non-forested patches
Study: 35192105
Drug: 0.25% tanfanercept,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% tanfanercept, twice daily for eight weeks
Study: 34634064
Drug: Weekly regret
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly regret lottery with activity trackers and daily text message reminders
Study: 34634064
Drug: Activity trackers
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity trackers and daily text message reminders (control arm)
Study: 33964194
Drug: Topical Dorema
Normalized name: Dorama-Neo
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Dorema ammoniacum cream
Study: 36280536
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication (Open Group)
Study: 36280536
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication (Hidden Group)
Study: 36280536
Drug: Study-supervised taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study-supervised taper and discontinuation of ineffective antidepressant medication
Study: 33471361
Drug: Traditional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional antibiotic therapy (from days 3 to 10 of the menstrual cycle)
Study: 33471361
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and molded sorbent-modified polyvinylpyrrolidone (FSMP) inserted from days 5 to 10
Study: 33471361
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and FSMP
Study: 32740576
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injection (≥1 ml per time)
Study: 32740576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hyaluronic acid injection)
Study: 32143630
Drug: Conventional tools
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tools (free internet access, pharmaceutical pocket guide, pocket guide antibiotic therapy)
Study: 33599552
Drug: Intravitreal anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF injections (ranibizumab or aflibercept)
Study: 32877722
Drug: Standard high-calorie,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high-calorie, high-fat meal administered via naso-gastro-intestinal tube
Study: 36506775
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg midazolam
Study: 32144895
Drug: Moderate-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose exercise (8 kcal/kg of body weight per week)
Study: 32144895
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (20 kcal/kg of body weight per week)
Study: 35901476
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 20 mL of bupivacaine (0.25%)
Study: 35901476
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 20 mL of bupivacaine (0.25%) and 100 mg magnesium sulphate
Study: 35901476
Drug: Sham ESPB
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ESPB (2 mL normal saline)
Study: 34406172
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C Solution (VCS)
Study: 34406172
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Thiosulfate Solution (STS)
Study: 33528911
Drug: (-)-OSU6162 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-OSU6162 15 mg b.i.d. for 4 weeks, then 30 mg b.i.d. for 4 weeks, then 45 mg b.i.d. for 4 weeks
Study: 35915011
Drug: Online training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online training in pain measurement using structured scales (e.g., Face Scale for Pain Assessment of Preterm Infants, Japanese version of the Premature Infant Pain Profile)
Study: 36002315
Drug: Trimetazidine 35
Normalized name: trimetazidine 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35 mg twice per day for 3 months
Study: 33661184
Drug: High-definition transcranial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-definition transcranial direct current stimulation (HD-tDCS) at 2 mA for 20 minutes twice daily over 5 days
Study: 39318787
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT)
Study: 33303314
Drug: SGB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB therapy with 7 mL 0.5% ropivacaine
Study: 33303314
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SGB therapy)
Study: 35538377
Drug: 100,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 IU of Vitamin D2 once weekly for twelve weeks (Group 2)
Study: 35538377
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU of Vitamin D2 daily for ten days followed by 2,000 IU of Vitamin D3 daily for 74 days (Group 3)
Study: 32175647
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg once daily for 48 hours before surgery and 0.5 mg twice daily for 5 days after surgery)
Study: 33783622
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control therapy (antiarrhythmic drugs or catheter ablation)
Study: 34259409
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (0.25 g each time, twice daily) for 8 weeks
Study: 36203788
Drug: Continuous preoperative
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous preoperative unilateral ESPB (20mL bupivacaine 0.25% bolus then 6 mL/h 0.1% for 48 hours)
Study: 36203788
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) morphine (0.01 mg/kg/h)
Study: 35323474
Drug: Brown seaweed
Normalized name: seaweed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brown seaweed extract (500 mg/d)
Study: 32332648
Drug: Transvaginal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transvaginal electrical stimulation (TVES) for 3 times with EMG-triggered neuromuscular stimulation twice
Study: 34032715
Drug: Other chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other chemotherapeutic agents
Study: 36871476
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy alone
Study: 33694253
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of nanoencapsulated eugenol (NE)
Study: 33461852
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized JC pollen extract
Study: 33567016
Drug: Coconut water-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coconut water-based solution (G1)
Study: 35093409
Drug: Tocovid SupraBio
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tocovid SupraBio 200mg and pentoxifylline 400mg orally twice daily for one year
Study: 34577869
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity extracorporeal shock wave therapy (LiESWT) with 0.25 mJ/mm2 intensity, 3000 pulses, and 3 pulses/s, once weekly for 4 weeks
Study: 34577869
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity extracorporeal shock wave therapy (LiESWT) with 0.25 mJ/mm2 intensity, 3000 pulses, and 3 pulses/s, once weekly for 8 weeks
Study: 34577869
Drug: Sham LiESWT
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham LiESWT treatment without energy transmission
Study: 33493544
Drug: Daily Undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Undulating Programming (DUP)
Study: 34965026
Drug: Polyvalent mechanical
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent mechanical bacterial lysate (PMBL) administered sublingually for 12 weeks